Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.41 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
| ▸ | PGR | P06401 | 2/20 | 0.39 |
| ▸ | AR | P10275 | 2/20 | 0.39 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.37 |
| ▸ | CARM1 | Q86X55 | 3/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 3/20 | 0.36 |
| ▸ | PARG | Q86W56 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13814713 | 0.81 | HTR2A (0.42) | HTR2ASLC6A4KCNH2SCN5ASCN9A | |
| SCHEMBL6961006 | 0.81 | ERBB2 (0.54) | KCNH2SCN5ASCN9A | |
| SCHEMBL14586641 | 0.81 | TEAD4 (0.48) | HTR2ASLC6A4KCNH2SCN5ASCN9A | |
| SCHEMBL6961127 | 0.79 | PGR (0.49) | PGRARSMN1; SMN2 | |
| SCHEMBL27428997 | 0.78 | MAPT (0.45) | SMN1; SMN2 | |
| SCHEMBL446449 | 0.77 | AR (0.47) | HTR2ASLC6A4KCNH2AR | |
| SCHEMBL21340879 | 0.75 | SLC6A4 (0.40) | HTR2ASLC6A4KCNH2PARGNPC1 | |
| SCHEMBL13011575 | 0.75 | TEAD4 (0.50) | HTR2ASLC6A4KCNH2ARSMN1; SMN2 | |
| SCHEMBL28452075 | 0.74 | SLC6A4 (0.45) | HTR2ASLC6A4KCNH2AR | |
| SCHEMBL3530110 | 0.72 | TDP1 (0.54) | PGRSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | HTR2A 435/4885SLC6A4 1036/4885KCNH2 1995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.